Primary percutaneous coronary intervention (PPCI) is the recommended treatment for patients with acute ST-segment elevation myocardial infarction (STEMI). Despite substantial evidence of its effectiveness, only 40-45% of European STEMI patients are currently treated with PPCI and there are large differences in this proportion between different European countries. Several studies have emphasised that PPCI delivery is complex, with multiple potential barriers to implementation, but there is no comprehensive research estimating the significant characteristics, factors and structures that determine the diffusion of PPCI in Europe. The lack of complete implementation and large national and regional differences arise from the interplay between technology, patients, policy makers, culture and resources. Explanations for the variation in treatment access still remain a puzzle and access to valid data is needed.
reinfarctions. [4] [5] [6] [7] Since then, a growing body of scientific knowledge favouring PPCI over fibrinolytic therapy has accumulated and meta-analyses show reduction in mortality with PPCI. 3, 5, [8] [9] [10] [11] [12] [13] Guidelines from the European Society of Cardiology (ESC) and from the American College of Cardiology (ACC)/American Heart Association (AHA) recommend PPCI as the preferred reperfusion strategy for patients with STEMI, if:
• first medical contact-to-balloon time or door-to-balloon time is less than 90-120 minutes;
• the interventionist is experienced (performs >75 PCI cases per year); and
• the patient is treated in a high-volume centre (one that performs >36 PPCI cases per year).
2,3,10, [14] [15] [16] Despite these recommendations, only 40-45% of European STEMI patients are currently treated with PPCI and large variations in treatment availability between countries have been reported. 15 Knowledge about the challenges of introducing new technologies into clinical practice is substantial. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] It is known to be a complex mix of medical, organisational, patient-related, regulatory and economic factors. Although many studies have sought factors to explain international and national variations in access to treatment, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] few have succeeded in translating gained knowledge into practice.
The emergence of the evidence of PPCI as life-saving therapy without its effective dissemination into clinical practice represents an urgent public health problem. This article describes the current situation of PPCI implementation and provides an overview of possible barriers to implementation of PPCI in Europe. 
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Barriers to Implementation of Primary Percutaneous Coronary Intervention
Timely Delivery
The success of PPCI depends highly on timely access, and system delays have shown to be independently associated with case fatality rates. 8, 36 Across Europe the majority of STEMI patients present to community hospitals without PPCI facilities, so the need for well-functioning regional pre-hospital systems for early diagnosis and immediate transport to a PPCI centre is crucial. Patients diagnosed by pre-hospital electrocardiogram (ECG) and transferred directly to a PPCI centre have a lower mortality. 37 The difficulty of providing timely access to appropriate facilities within the recommended timeframe (90-120 minutes or less from first medical contact to initiation of reperfusion) is one of the major barriers to PPCI delivery. Studies have shown that widespread adoption of PPCI was potentially limited by anticipated transport delays and practicalities associated with the transfer of patients from non-invasive hospitals to PPCI centres. 8, 36, [38] [39] [40] [41] [42] [43] However, meta-analyses suggest that PPCI is superior to fibrinolysis even when it requires inter-hospital transfer, 8, 44 and that the advantages of PPCI over fibrinolysis are limited to hospitals with a high or intermediate volume of cases. These findings have prompted some European countries to establish PPCI networks in which patients bypass or are transferred immediately from local hospitals to specialist centres to reduce system delay. 10, 45 These networks have shown impressive reductions in case fatality rates. 10, 36, 37, 46 This approach requires centralised and co-ordinated communication and
transfer organisation between local hospitals, PPCI hospitals and the emergency medical system (EMS). Networks require the availability of ambulances with 12-lead ECG capability and appropriately trained paramedics, which is not the case in many European countries today.
The influence of EMS organisation in Europe on the implementation of PPCI has not yet been estimated, but is probably important.
Because of these access and infrastructure issues, and the critical importance of time to treatment, fibrinolysis may be generally preferred in hospital systems that cannot meet the time goal for PPCI. 47 However, even in patients for whom fibrinolysis is successful, the guidelines now recommend angiography and in many cases percutaneous coronary intervention (PCI) within 24 hours, which further underlines the need to establish PPCI networks. 16 
Infrastructure and Organisation
The delivery of PPCI requires appropriate cardiac catheterisation laboratories with specialised and experienced staff. Lack of cardiac nurses, technicians and other trained staff may threaten the sustainability of PPCI. Outcomes from STEMI are related to appropriate staff education and specialisation, as well as a sufficient volume of procedures. 45, 48, 49 An extensive survey in Canada identified the lack of catheterisation laboratories and experienced staff as primary barriers to complete implementation. 43 In 2008, the UK National Health Service (NHS) published a comprehensive report on PPCI implementation. 42 Based on qualitative interviews, the report highlighted some important barriers towards implementation of PPCI among employees. They expressed concerns about the availability of sufficient equipment, training and hospital beds for unplanned admissions. They also worried about disruption to the planned working day programme delaying elective cases, and some staff were not happy to work across role boundaries. 42 Another principal barrier was the 24-hour requirement for specialist staff to be available to respond in an emergency 43, 48 and resistance towards a change in working hours.
In Europe, the optimal rate of use of PPCI in STEMI remains unknown, so there are no standards for organisation of systems or training of clinicians and other health personnel. 9, 45, 50, 51 Appropriate staffing is essential to achieve anticipated outcomes, and the requirement for additional resources might be a major barrier to achieving the staff requirements in some countries. Regional
Barriers to Implementation of Primary Percutaneous Coronary Intervention in Europe 35 networks with specialist PPCI centres might again be the best solution to overcome this barrier. 10, 36, 52, 53 Modern healthcare systems are complex and often specialised into many branches that correspond to several broad disease categories. 62 For this group of patients, physicians employed by managed-care organisations were far less likely than physicians in the fee-for-service sector to believe that angiography was necessary, and invasive cardiologists were more likely than non-invasive cardiologists to believe that the procedure was necessary. 62 In the face of cost-containment activities, considerably more information is needed about the kinds of financial arrangements and incentives that influence physicians' approaches to providing care.
Empirical research will be particularly valuable in this respect.
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Limitations of the Existing Literature
In the field of PPCI delivery, a number of barriers to complete implementation have been identified and strategies have been suggested to overcome these barriers. Table 1 provides an overview of some of the identified barriers. However, both the barriers and solutions identified are based more on intuition rather than empirical data, and might be difficult to transfer from one healthcare system to another. 28, 34, 42, 45 Studies have mainly examined variations across smaller areas, and few studies have taken into account the interaction between the different barriers, as well as the national context in which they arise. 20, 28, 57, 63, 64 Each healthcare system is adjusting its activities to a specific social, historical and cultural setting, in which many different factors may influence the performance and fundamental objectives of the healthcare system. Classic approaches to implementing new technology often fail because little attention is given to the variety of barriers that need to be changed in a certain context. 20 In a systematic literature review from 1999, Cabana et al.
found that only 58% of the 120 surveys examined more than one barrier. 20 In addition, many such health service studies are carried out in the US and Canada, so the results may have limited applicability to a European setting.
While a substantial amount of attention has been paid to studies comparing the effect of economic and governmental regulations on implementations across countries, rather less attention has been devoted to examine in detail the factors that influence clinical decision-making in everyday clinical practice. 26, 42 The major barrier to this type of research is the lack of good nationwide registries that allow inter-and cross-country comparisons at the patient level.
Population-based rates for particular medical procedures may be based on many thousands of decisions taken on many thousands of Aggregated data do not uncover differences between patients treated at each type of hospital and setting that might affect the rate of use. [65] [66] [67] Moreover, studies are often based on selected trial populations of patients with STEMI admitted to hospital led by enthusiasts and those who are keen on inducing changes. This selection tendency may result in an overestimation of the use of reperfusion therapy, since one might expect patients in clinical trials to receive more attention and better care than non-trial patients. 8, 11 A clearer understanding of factors in the clinical setting is likely to refine the decision on quality improvement initiatives and to maximise the technology uptake and guidelines adherence.
Several studies have sought after factors to explain patterns of practice variation, but few have succeeded, particularly in international comparisons. Most detailed studies evaluating adherence to practice guidelines have been conducted at a regional or a national level, mainly due to logistic reasons but also simply due to lack of data availability. Much could be learned by a more detailed examination of broad international practice patterns.
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Opportunities for Improvement in Use of Primary Percutaneous Coronary Intervention
The Need for Good Cardiac Registry Data in Europe Systematic documentation and surveillance of health status, treatment schemes and treatment outcomes of heart patients are needed in all European countries. 26, 65 Databases are important to address the full diversity of access to treatment between regions and countries; to target initiatives including implementation strategies;
and to compare healthcare systems against each other. Remarkably few sources exist on incidence data on ischaemic heart disease (IHD). 26 The incidence serves as an approximation of the underlying demand for IHD healthcare services -in other words as a source for organising a PPCI strategy to meet actual future need. Obtaining adequate data to conduct precise quantitative comparisons of the impact of technological change on changes in expenditures and outcomes across countries will help to redirect resources to other parts of the healthcare system. 26 
Pan-European Project
In an attempt to reduce differences in treatment access across 
Conclusion and Future Directions
Variation across geographic areas in the use of PPCI is common among patients with acute myocardial infarction, and even though many studies have sought barriers to explain this variation, few have succeeded in translating this knowledge into practice. The implementation of PPCI has multiple barriers, and to provide PPCI in an effective, high-quality and timely manner is a great challenge.
Streamlining the processes of care involves patients, physicians and support staff.
An understanding of the potential factors or characteristics that explain the diffusion of PPCI will suggest policy mechanisms and instruments to control and regulate the adoption of PPCI. Such knowledge will be necessary to increase the effectiveness and efficiency of the diffusion, and will be the first step in ensuring equal access to PPCI treatment for STEMI patients in Europe. Better monitoring of STEMI incidence and prospective registration of PPCI in all countries is required to document improvements in healthcare and to identify areas where further effort is required. This type of data collection will require multidisciplinary co-operation. 65 n
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